Alzheimer's disease genes aid the search for preventive drugs doi:10.1038/news.2011.433 Proposed trials of candidate drugs before symptoms appear offer hope of more effective treatments. Full Text
Charities seek cut of drug royalties doi:10.1038/475275a Non-profits that support medical research are angling for a share of the proceeds and intellectual-property rights. Full Text
Cell signalling caught in the act doi:10.1038/475273a Receptor imaged in embrace with its G protein. Full Text
Regulations proposed for animal—human chimaeras doi:10.1038/475438a UK lays out first framework to govern ethically sensitive research field. Full Text
Crossing over to bispecificity doi:10.1038/scibx.2011.783 An approach to produce bispecific antibodies derived from existing monoclonal antibodies could minimize immunogenicity and provide pharmacokinetics on par with natural antibodies while maintaining the ability to inhibit two targets at once. Full Text
Timing of patent filing and market exclusivity doi:10.1038/nrd3494 This analysis article looks at the relationship between patent filing date, market authorization date and expected duration of market exclusivity over the period 2000 to 2010. Full Text
Fresh from the pipeline: Pirfenidone doi:10.1038/nrd3495 Pirfenidone (Esbriet; Intermune) has been granted marketing authorization in Europe for the treatment of idiopathic pulmonary fibrosis. In October 2008 it was approved for the same indication in Japan, where it is marketed as Pirespa. Full Text
Metabolic disease: New role for HDACs in glucose homeostasis doi:10.1038/nrd3483 Two papers have found a novel mechanism involved in the regulation of glucose production by the liver, implicating class IIa histone deacetylases (HDACs) as promising therapeutic targets. Full Text
Inflammatory disorders: Steroids modulate microglia-mediated inflammation doi:10.1038/nrd3485 Researchers have identified a gene-repression pathway that regulates microglia-induced inflammation. This pathway could be targeted using certain ERβ ligands as a new approach to treat neurodegenerative diseases. Full Text
Cancer: Autophagy presents Achilles heel in melanoma doi:10.1038/nrd3482 Melanoma cells with an activated RAS–MEK–signalling pathway fail to induce autophagy upon leucine withdrawal. The combination of an autophagy inhibitor and a leucine-free diet can synergistically inhibit tumour growth. Full Text
How were new medicines discovered? doi:10.1038/nrd3480 Analysis suggests a target-centric approach for first-in-class drugs, without consideration of an optimal molecular mechanism of action, may contribute to the current high attrition rates and low productivity in pharmaceutical research. Full Text
Novel therapeutic targets for the treatment of heart failure doi:10.1038/nrd3431 This review of new therapeutic targets and future perspectives of new drugs looks also at the possible explanations for the discrepancy between data from Phase II and Phase III trials. Full Text
Structure of the human histamine H1 receptor complex with doxepin doi:10.1038/nature10236 The crystal structure of the H1R complex with doxepin, a first-generation H1R antagonist, sheds light on the molecular basis of H1R antagonist specificity against H1R. Full Text
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition doi:10.1038/nm.2377 Inhibition of Cdk1 represents a plausible strategy for expanding the utility of PARP inhibitors to BRCA-proficient cancers. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment